Independence Capital Asset Partners’s Acceleron Pharma XLRN Stock Holding History

Independence Capital Asset Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-24,314	Closed	-$605K	–	44
2015 Q3	$605K	Buy	+24,314	New	+$731K	0.85%	35
2015 Q2	–	Sell	-363,136	Closed	-$13.8M	–	73
2015 Q1	$13.8M	Buy	363,136 +25,054	+7%	+$996K	2.15%	20
2014 Q4	$13.2M	Buy	+338,082	New	+$11.8M	1.82%	25
2014 Q3	–	Sell	-15,500	Closed	-$527K	–	98
2014 Q2	$527K	Sell	15,500 -120,923	-89%	-$4.04M	0.07%	68
2014 Q1	$4.71M	Buy	+136,423	New	+$6.16M	0.78%	45
2013 Q4	–	Sell	-37,557	Closed	-$835K	–	110
2013 Q3	$835K	Buy	+37,557	New	+$810K	0.14%	59

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

PVMCI

Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Independence Capital Asset Partners's XLRN Position: Q4 2015 in Review

Independence Capital Asset Partners sold out of Acceleron Pharma (XLRN) in Q4 2015, closing a stake of 24,314 shares — an estimated $605K sold.

Independence Capital Asset Partners first reported a position in XLRN in Q3 2013 and held it in 6 quarters. The position peaked at $13.8M in Q1 2015. 125 funds tracked by Wall St. Rank hold XLRN as of Q4 2015.

Independence Capital Asset Partners reported no remaining Acceleron Pharma position as of Q4 2015 after selling out during the quarter.
Independence Capital Asset Partners sold 24,314 Acceleron Pharma shares in Q4 2015, an estimated $605K.
Independence Capital Asset Partners first reported a position in Acceleron Pharma in Q3 2013 and held it in 6 quarters.
Independence Capital Asset Partners's Acceleron Pharma position peaked at $13.8M in Q1 2015.
125 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2015.

Based on Independence Capital Asset Partners's 13F filing for Q4 2015, filed 5 Feb 2016.